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In the context of a phase III trial comparing in advanced non-small cell lung cancer (NSCLC) sequential to conventional administration
of cisplatin-based chemotherapy and paclitaxel, we evaluated the activity of paclitaxel as second-line chemotherapy and investigated
any relation of its efficacy with the type of failure after cisplatin. Patients received three courses of induction GIP (gemcitabine,
ifosfamide, cisplatin). Non-progressing patients were randomised between three further courses of GIP or three courses of paclitaxel.
Second-line paclitaxel was given to patients with primary failure (PF) to GIP and to those progressing after randomisation to further
GIP (secondary failure or SF). One hundred sixty patients received second-line paclitaxel. Response rates were 7.7% for PF and 11.6%
for SF (P¼0.42). Median survival times (calculated from paclitaxel start) were 4.1 and 7.1 months for PF and SF (P¼0.002). In
multivariate analysis, three variables were independently associated with better survival: SF (hazard ratio (HR)¼1.55, 95% confidence
interval (CI) 1.08–2.22; P¼0.02), normal haemoglobin level (HR¼1.56, 95% CI 1.08–2.26; P¼0.02) and minimal weight loss
(HR¼1.79, 95% CI 1.26–2.55; P¼0.001). Paclitaxel in NSCLC patients, whether given for primary or for SF after cisplatin-based
chemotherapy, demonstrates activity similar to other drugs considered active as second-line therapy.
British Journal of Cancer (2007) 96, 1644–1649. doi:10.1038/sj.bjc.6603772 www.bjcancer.com
Published online 1 May 2007
& 2007 Cancer Research UK
Keywords: chemotherapy; sequential; advanced non-small cell lung cancer
                                               
First-line cisplatin-based chemotherapy has demonstrated a
palliative effect in advanced and metastatic non-small cell lung
cancer (NSCLC) with a significant survival improvement, better
symptoms control and reduced cost compared with supportive
care only (Non Small Cell Lung Cancer Collaborative Group, 1995).
Second-line chemotherapy with taxanes has also been shown
effective (Barlesi et al, 2006; Sculier, 2006). Docetaxel, which has
been shown to significantly improve survival compared with
supportive care only (Shepherd et al, 2000), is currently proposed
as second-line chemotherapy in NSCLC patients failing after
platinum-based chemotherapy (Socinski et al, 2003; Pfister et al,
2004; European Lung Cancer Working Party, 2006). Paclitaxel, the
other available taxane, has also demonstrated potential activity in
the same indication in a few phase II studies (Socinski et al, 1999;
Juan et al, 2002; Socinski et al, 2002; Sculier et al, 2002a; Buccheri
and Ferrigno, 2004; Ceresoli et al, 2004; Yasuda et al, 2004). There
is only one randomised phase II study, including 71 patients,
which directly compares paclitaxel to docetaxel (Esteban et al,
2003).
In the present study, we studied all the patients included in a
randomised phase III trial of the European Lung Cancer Working
Party (ELCWP) who received paclitaxel as second-line chemo-
therapy. The primary aim of the above-mentioned phase III trial
was to compare sequential administration of cisplatin-based
chemotherapy followed by paclitaxel to a conventional cisplatin-
based chemotherapy with paclitaxel as salvage therapy. The aim of
the present study was the analysis of the activity and toxicity of
paclitaxel when given as second-line chemotherapy in NSCLC
patients, in PF or secondary failure (SF) after first-line cisplatin-
based chemotherapy. Institutions that participated in the trials are
set as Appendix section.
PATIENTS AND METHODS
Selection criteria
Eligibility criteria for registration in the study included:
  histologically or cytologically proven NSCLC
  previously untreated stage IV or stage IIIB with malignant
pleural effusion patients
  Karnofsky performance status (PS) X60
Other eligibility criteria were those previously published by the
ELCWP (Sculier et al, 2002b).
Treatment
Eligible patients received three courses of induction GIP
(gemcitabine (1gm
 2 on days 1 and 8)þifosfamide (3gm
 2 on
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sday 1)þcisplatin (50mgm
 2 on day 1)) every 3 weeks. At
evaluation, non-progressing patients (stable disease or objective
responses) were randomised between three further similar courses
of GIP or three courses of paclitaxel (225mgm
 2 over 3h after
appropriate antihypersensitivity premedication), every 3 weeks.
Treatment was given until best response. Patients progressing after
randomisation were treated with paclitaxel if in the GIP arm or GIP
if in the paclitaxel arm. Paclitaxel at the above mentioned dosage
was also given in case of disease progression (PD) after the three
cycles of induction GIP.
Patients with failure to the induction GIP (primary failure or PF)
and patients who progressed after randomisation to another three
courses of GIP (SF) constitute the population of the present study.
The administration of a course of paclitaxel required that
haematological (neutrophils 41500mm
 3 and platelets
4100000mm
 3) function had recovered. If the delay between
two courses was more than 6 weeks, the patient went off-treatment.
If neutrophil nadir was o500mm
 3 and platelet nadir
o25000mm
 3, dosage of paclitaxel was reduced to 75% of the
previously administered dose.
Criteria of evaluation
Patients were evaluated for response after the completion of three
chemotherapeutic courses. Responses were assessed according to
the usual criteria (Sculier et al, 2002b). Complete remission was
defined as the disappearance of all signs of disease, for at least 4
weeks. In measurable disease, partial response (PR) was defined as
X50% decrease of the total tumour load in two observations not
less than 4 weeks apart, in the absence of new lesions or
progression in any existing lesion. Tumour load was estimated
as the tumour area calculated by the multiplication of the longest
diameter by the greatest perpendicular diameter. In assessable
disease, PR was defined as an estimated decrease in tumour size
of 50% or more. Progression (PG) was defined as an increase of
X25% in one or more measurable or assessable lesions or the
appearance of new lesion(s). All other circumstances were
classified as no change (NC). Early death due to PD before
evaluation, toxic death due to chemotherapy or early chemother-
apy discontinuation because of toxicity were considered as
treatment failures and incorporated in the evaluable patients.
In addition, we defined stabilisation as either PR or NC. Survival
was calculated from the start of second-line paclitaxel. WHO
criteria were used to assess toxicity.
Statistical methodology
Registration and randomisation were centrally performed by calling
the ELCWP central office at the Jules Bordet Institute in Brussels.
Survival curves were estimated using Kaplan–Meier method. The log
rank test was used to compare survival curves. P-values for testing
differences between proportions were calculated with w
2 tests or with
Fischer’s exact tests. A multivariate analysis for adjustment of the
treatment effect taking into account prognostic factors was
performed by fitting the data with a Cox model for duration of
survival and a logistic regression model for objective response. The
result of a statistical test was considered as significant when level
of the Po0.05. All reported P-values are two-sided. Paclitaxel dose
intensity (DI) was calculated as the ratio of the cumulative dose to
the actual duration of treatment (and expressed in mgm
 2 and per
week). Relative DI was the ratio of the achieved DI divided by the
planned DI that is 75mgm
 2 per week.
RESULTS
A total of 493 patients were registered in the phase III trial between
January 2000 and February 2004. Eight (1.6%) were ineligible. The
principal characteristics at registration of the 485 eligible patients
were previously published (Sculier et al, 2007). At the evaluation
after GIP courses, PR, NC and PD were documented in 174, 115
and 123 patients, respectively. Of the 123 progressing after initial
GIP chemotherapy patients (PF), 91 (74%) received paclitaxel as
salvage treatment. Twenty-three had no further anticancer therapy,
six received radiotherapy and three other chemotherapeutic
regimens. Characteristics of the 91 patients at the time of
second-line paclitaxel are shown in Table 1. Among the 140
patients randomised to further GIP, 69 (49%) received second-line
paclitaxel at relapse (SF). Among those 69, 39 had responded and
30 demonstrated NC to the initial GIP chemotherapy. Their
characteristics are also shown in Table 1.
Type of response in PF and SF groups is shown in Table 2.
Objective response (OR) was documented in 15 patients: seven (7.7
%) in the PF group and eight (11.6%) in the SF group. NC was
observed in 27 patients, nine (9.9%) in PF and 18 (26.1%) in SF.
There was no significant (P¼0.42) difference in OR between the
two groups. On the contrary, in terms of stabilisation rate
(ORþNC), the difference between the two groups reached
Table 1 Characteristics at registration of the patients at time of second-
line paclitaxel
PF SF
N 91 69 P-value
Gender
Male 77 (85%) 52 (75%) 0.16
Female 14 (15%) 17 (25%)
Age
o60 years 50 (55%) 40 (58%) 0.75
X60 years 41 (45%) 29 (42%)
Histology
Squamous 14 (15%) 19 (27%) 0.10
Adenocarcinoma 55 (60%) 40 (58%)
Other 22 (24%) 10 (15%)
Performance status
p70 35 (44%) 18 (38%) 0.58
80–100 44 (56%) 29 (62%)
Unknown 12 22
Type of lesion
Assessable 25 (28%) 15 (22%) 0.46
Measurable 66 (72%) 54 (78%)
Stage
III 3 (3%) 1 (1%) 0.63
IV 87 (97%) 68 (99%)
Unknown 1 0
Weight loss
a
o5% 48 (53%) 39 (64%) 0.24
X5% 42 (47%) 22 (36%)
Unknown 1 8
Haemoglobinemia
12–18gdl
 1 22 (25%) 30 (49%) 0.003
o12gdl
 1 66 (75%) 31 (51%)
Unknown 3 8
Response to initial GIP
PR — 39 —
NC — 30
PD 91 —
NC¼no change; PD¼progressive disease; PF¼primary failure; PR¼partial
response; SF¼secondary failure.
aWeight loss between first induction GIP and first
paclitaxel infusion.
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ssignificance (P¼0.006). The results remained unchanged after
adjustment for haemoglobinemia at the start of paclitaxel. In the
SF group, we looked at the impact of the delay between the time of
documentation of the first response or NC after the initial GIP
(date of the third cycle of induction GIP plus 21 days) and the time
of documentation of the first progression. The median time to
progression (TTP) after the first GIP was 4 months (range 0.7–22.1
months). The SF group was divided according to the median TTP
in an early progression group (SF1; TTP below the median) and a
late progression group (SF2; TTP above the median). Three (9.1%)
and five (13.9%) patients demonstrated PR in the SF1 and SF2
groups, respectively. Detailed results are shown in Table 2. There
was no statistical difference in OR rate between PF and SF1 or SF2
groups (P¼0.30). All the analyses were performed in an intent-to-
treat level.
Considering patients’ characteristics at the start of paclitaxel, no
significant prognostic factor for response can be identified in
univariate analysis (data not shown), with the exception of a
favourable initial response to GIP. Patients with OR to GIP had
higher OR rates to paclitaxel (18%) than those without (7%)
(P¼0.05). The same analysis was performed for the patients with
disease stabilisation. The results are shown in Table 3. Significantly
favourable prognostic factors were Karnofsky PS above 70
(P¼0.03), normal haemoglobin level (P¼0.001), objective re-
sponse to initial GIP (P¼0.003) and late SF (P¼0.007). When we
divided the SF group according to more standard delays such as 3
or 6 months, the same results were found. All the variables with a
Po0.20 were included in a multivariate analysis. Two factors
found to be predictive of stabilisation in patients receiving second-
line paclitaxel: objective response to induction GIP (odds ratio
5.28, 95% confidence interval (CI) 2.01–13.87, P¼0.001) and
normal haemoglobin level (odds ratio 3.62, 95% CI 1.49–8.77,
P¼0.004).
Survival rates are shown in Table 4 and Figure 1. Four patients
were lost to follow up and excluded from the survival analysis. At
the time of the analysis, 144 patients were dead (85 out of 90 in PF,
31 out of 32 in SF1, 28 out of 34 in SF2). Median survival time
(MST) was 4.1 months (95% CI 3.5–4.7 months) and 7.1 months
(95% CI 5.3–8.9 months) for PF and SF group, respectively
(hazard ratio (HR) 1.67, (95% CI 1.19–2.33; P¼0.003). When SF
patients were divided into early and late progression, MST were 6.5
(95% CI 4.9–8.0 months) and 8.2 months (95% CI 4.1–12.2
months), respectively. HR for the comparisons among the three
groups were 1.35 for PF vs SF1 (95% CI 0.89–2.05, P¼0.15), 2.01
for PF vs SF2 (95% CI 1.30–3.09, P¼0.001) and 1.48 for SF1 vs SF2
(95% CI 0.89–2.46; P¼0.14). Similar results were found when
patients with SF were separately analysed according to a 3 or a 6
months interval between first OR documentation and first
progression (data not shown).
Results of the prognostic factors analysis for survival are
summarised in Table 5. In univariate analysis, variables signifi-
cantly associated with better survival were: good PS (P¼0.001),
minimal weight loss (Po0.001), normal haemoglobin level
(P¼0.003), objective response to initial GIP (P¼0.02) and
progression free interval (PF vs SF, P¼0.002). All these variables,
excepting PS because of a very high rate of missing values, were
selected for a Cox multivariate analysis. Three variables were
Table 2 Response rates to second-line paclitaxel in patients with non-
small cell lung cancer
PF SF SF1 SF2
N 91 (57%) 69 (43%) 33 36
Partial response 7 (7.7%) 8 (11.6%) 3 (9.1%) 5 (13.9%)
No change 9 (9.9%) 18 (26.1%) 9 (27.3%) 9 (25%)
Progression 61 (67%) 31 (44.9%) 15 (45.5%) 16 (44.4%)
Early death malignant disease 8 (8.8%) 5 (7.2%) 4 (12.1%) 1 (2.8%)
Toxic death 1 (1.1%) 1 (1.4%) 1 (3%) —
High toxicity 4 (4.4%) 1 (1.4%) — 1 (2.8%)
Unassessable 1 (1.1%) 5 (7.2%) 1 (3%) 4 (11.1%)
PF¼primary failure; SF¼secondary failure; SF1¼early secondary failure; SF2¼late
secondary failure.
Table 3 Univariate analysis of prognostic factors determining stabilisation
with second-line paclitaxel
Clinical benefit P-value
Gender
Male 32/129 (25%) 0.50
Female 10/31 (32%)
Age
o60 years 20/90 (22%) 0.21
X60 years 22/70 (31%)
Histology
Squamous 9/33 (27%) 0.94
Adenocarcinoma 24/95 (25%)
Other 9/32 (28%)
Karnofsky
p70 9/53 (17%) 0.03
80–100 26/73 (36%)
Type of lesion
Assessable 8/40 (20%) 0.41
Measurable 34/120 (28%)
Weight loss
a
o5% 28/87 (32%) 0.14
X5% 13/64 (20%)
Haemoglobinemia
12–18gdl
 1 23/52 (44%) 0.001
o12gdl
 1 18/97 (19%)
Response to GIP
Objective response 18/39 (46%) 0.003
No objective response 24/121 (20%)
Type of failure
Primary failure 16/91 (18%) 0.007
SF1 12/33 (36%)
SF2 14/36 (39%)
GIP¼gemcitabine, ifosfamide, cisplatin; SF1¼early secondary failure; SF2¼late
secondary failure.
aWeight loss between first induction GIP and first paclitaxel
infusion.
Table 4 Survival rates of patients with non-small cell lung cancer treated
with second-line paclitaxel
PF SF P-value
MST 4.1 months
(95% CI: 3.5–4.7)
7.1 months
(95% CI: 5.3–8.9)
0.002
HR 1.67
(95% CI : 1.19–2.33)
0.003
SF1 SF2
MST 4.1 months 6.5 months 8.2 months 0.004
HR 1.48 (95% CI: 0.89–2.46) 0.14
CI¼confidence interval; HR¼hazard ratio; MST¼median survival time; PF¼prim-
ary failure; SF¼secondary failure; SF1¼early secondary failure; SF2¼late secondary
failure.
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sindependently associated with better survival: SF (HR¼1.55, 95%
CI 1.08–2.22; P¼0.02), normal haemoglobin level (HR¼1.56,
95% CI 1.08–2.26; P¼0.02) and minimal weight loss (HR¼1.79,
95% CI 1.26–2.55; P¼0.001).
Data on dates and doses of paclitaxel courses were available for
148 out of 160 (92.5%) patients. Among them, 99 received at least
three courses and 23 received at least six courses. There were few
delayed administrations (5%) and dose reductions (4%). Calcu-
lated in the 99 patients who received at least three courses, the
DI ranged between 47 and 83mgm
 2week
 1 (median 70) and the
median relative DI was 94%. Similar results were obtained when
the analysis was performed in all 148 patients.
Toxicity was minimal. Twelve and 20 patients were not
assessable for non-haematological and haematological toxicities,
respectively. Grade III–IV non-haematological toxicity comprised
peripheral neuropathy (6%), infection (4%), cardiac (1%), nausea,
skin reaction and diarrhoea (o1% each). Grade III–IV leucopenia
and thrombopenia were observed in 11 and o1% of the patients,
respectively.
DISCUSSION
We found that paclitaxel is an active drug in both PF and SF,
although response rates and survival are better in SF patients,
especially in those with late SF.
Our study addressing, in fact, the question of the effectiveness of
paclitaxel as second-line chemotherapy in patients with advanced
NSCLC who failed first-line cisplatin-containing chemotherapy
presents some interesting peculiarities:
1. Paclitaxel as second-line chemotherapy was part of the design
of a prospective randomised phase III trial. Therefore, the
majority of progressing/relapsing patients could tolerate high
dose of paclitaxel (225mgm
 2) every 3 weeks as it was
predicted in the protocol.
2. In variance with other second-line phase II studies, patients
population in our study was homogeneous in terms of
previously administered chemotherapy, as all had received
the same initial cisplatin-based regimen.
3. Unlike in other studies, the patients who received paclitaxel
were not selected at the time of second-line treatment, thus,
allowing a better characterisation of the type of patients who
could benefit from second-line paclitaxel.
Therefore, our findings can be considered more relevant
information for implementation in clinical practice.
The main criticism of our study would be the decision to use
paclitaxel instead of docetaxel as second-line chemotherapy.
Nevertheless, at the time we designed our prospective phase III
trial, there were no published randomised studies confirming the
superiority of docetaxel vs best supportive care for relapsing
NSCLC patients. As both paclitaxel and docetaxel had demon-
strated interesting response rates as second-line treatment, in
phase II studies, and because docetaxel was not yet broadly
marketed, we decided to use paclitaxel, being the only drug
available to all participating centres of the ELCWP.
It is of interest that the results observed with paclitaxel in phase
II studies compared well with those obtained with docetaxel in
randomised phase II and III trials. Response rates with paclitaxel
of the range of 0–38% in previously published studies (Socinski
et al, 1999, 2002; Juan et al, 2002; Sculier et al, 2002a; Buccheri and
Ferrigno, 2004; Ceresoli et al, 2004; Yasuda et al, 2004), and of the
order of 7.7 and 11.6% in PF and SF patients, respectively,
observed in the present study are similar to those with docetaxel,
ranging from 2.7 to 12.6% (Fossella et al, 2000; Shepherd et al,
2000; Gridelli et al, 2004; Hanna et al, 2004; Quoix et al, 2004;
Gervais et al, 2005; Schuette et al, 2005; Camps et al, 2006).
Furthermore, survival with second-line paclitaxel in our study,
significantly better for SF patients (7.1 months) than PF ones (4.1
months), was of the same magnitude than with second-line
docetaxel in published randomised studies, reporting median
survival rates (MST) ranging from 4.7 to 9.2 months (Fossella et al,
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Figure 1 Survival curves of the patients with NSCLC treated with
second-line paclitaxel.
Table 5 Univariate analysis of prognostic factors for survival in patients
receiving second-line paclitaxel
N patients/
N events
MST
(months) P-value
Gender
Male 126/116 4.8 0.30
Female 30/28 6.5
Age
o60 years 88/78 5.0 0.95
X60 years 68/66 5.3
Type of lesions
Assessable 38/34 5.5 0.92
Measurable 118/110 4.9
Histology
Squamous 31/29 6.2 0.70
Adenocarcinoma 93/84 4.6
Other 32/31 4.7
Karnofsky
p70 52/50 3.9 0.001
80–100 73/66 6.6
Weight loss
a
o5% 87/77 6.1 o0.001
X5% 63/62 3.9
Haemoglobinemia
12–18gdl
 1 52/46 8.0 0.003
o12gdl
 1 96/91 4.3
Response to GIP
Objective response 37/32 7.9 0.02
No objective response 119/112 4.5
Progression-free interval
Primary failure 85/90 4.1 0.002
Secondary failure 59/66 7.1
GIP¼gemcitabine, ifosfamide, cisplatin; MST¼median survival time.
aWeight loss
between first induction GIP and first paclitaxel infusion.
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s2000; Shepherd et al, 2000; Gridelli et al, 2004; Hanna et al, 2004;
Quoix et al, 2004; Gervais et al, 2005; Schuette et al, 2005; Camps
et al, 2006). Similar were MST with paclitaxel in previous studies,
ranging from 4.5 to 14 months (Socinski et al, 1999, 2002; Juan
et al, 2002; Sculier et al, 2002a; Buccheri and Ferrigno, 2004;
Ceresoli et al, 2004; Yasuda et al, 2004). The equivalence of both
drugs was evaluated in one small randomised phase II study only.
No statistically significant difference was found in terms of
response rate (14 vs 3%) and median survival (105 vs 184 days)
(Esteban et al, 2003).
The most important finding of our study was the identification
of three groups of patients with distinct prognosis. Patients failing
during the initial cisplatin chemotherapy presented with the
poorest response rate and survival. Patients with SF could be
divided, according to the delay between the documentation of
stabilisation (PR or NC) to initial cisplatin and relapse, into a short
and a long delay group. The importance of treatment-free interval
is well known in small cell lung cancer with higher probability to
achieve a response with second-line chemotherapy if the treatment
free interval is in excess of 3 months (Postmus, 2005). We also
found that survival was influenced by progression-free interval in
advanced NSCLC patients when comparing among PF, SF1 and SF2
groups.
Related toxicity is an important parameter in deciding among
drugs with similar activity which one to use. We observed
infrequent grade III/IV toxicity associated with paclitaxel. Non-
haematological toxicities were of the same magnitude in the three
biggest docetaxel trials (Fossella et al, 2000; Shepherd et al, 2000;
Hanna et al, 2004) but more profound neutropenia were described
with docetaxel.
We observed that stabilisation rates and survival were influenced
by haemoglobin level. Haemoglobinemia can be influenced by
various factors like transfusion policy, use of erythropoietin or time
since end of platinum infusion. Haemoglobin levels used in the
prognostic factor analysis were measured at the time or near before
the first infusion of paclitaxel given as second-line therapy. We
cannot definitively exclude that previous transfusions or prior
erythropoietin administration influenced haemoglobin level at this
time. However, in our analysis, we took into account time since end
of platinum-based chemotherapy by considering the covariate type
of failure (PF vs SF after a short or long delay) and haemoglobi-
nemia remained a significant factor after adjustment for type of
failure. This means that even if the level of haemoglobin is
correlated to the type of failure, it brings some useful additional
independent information to explain further survival.
In conclusion, paclitaxel is a well-tolerated and active drug for
second-line therapy in patients with NSCLC failing or relapsing
after cisplatin-based chemotherapy. Although all progressing
patients could potentially benefit from paclitaxel use, we were
able to define a group with better prognosis. Patients with
stabilised disease (PR or NC) on initial cisplatin who relapsed
after a long progression-free interval have a higher likelihood to
respond to second-line paclitaxel and to have longer survival.
Furthermore, response and survival rates with paclitaxel seems
to be similar to those with docetaxel, although this needs to be
confirmed in a prospective randomised phase III trial.
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